Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01305993
Recruitment Status : Unknown
Verified February 2011 by SBPharmaceutical IND, Co., LTD.
Recruitment status was:  Not yet recruiting
First Posted : March 1, 2011
Last Update Posted : March 1, 2011
Information provided by:
SBPharmaceutical IND, Co., LTD

Brief Summary:
The purpose of this study is to determine efficacy of SB injection in Gastric Cancer.

Condition or disease Intervention/treatment Phase
Gastric Cancer Drug: SB injection Phase 2

Detailed Description:
All eligible patients will receive SB injection therapy for 6 cycles (14~21 days for each cycle). Efficacy will be evaluated every 3 cycles.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Gastirc Cancer
Study Start Date : May 2011
Estimated Primary Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Intervention Details:
  • Drug: SB injection
    Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months

Primary Outcome Measures :
  1. Evaluating Tumor Response Rate [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Pain Scores on the Visual Analog Scale [ Time Frame: 4 months ]
  2. Evalute patient's performance by measuring Eastern Cooperative Oncology Group scale [ Time Frame: 4 months ]
  3. Determine duration of response rate by measuring time to progression [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age of 18years or over
  • Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage and with measurable lesions
  • Life expectancy >/= 5 months
  • Not available to any of resectable surgery or radiotherapy
  • Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as defined by

    1. Absolute neutrophil count(ANC)>/= 1.0 x 10^9/L, Platelet count >/= 75 x 10^9/L
    2. Total bilirubin < 2.0mg/dL
    3. Aspartate Aminotransferase(AST) and/or Alanine Aminotransferase(ALT) < 5 x Upper Limit Normal(ULN)
    4. creatinine < 2 x ULN
  • ECOG status 0 to 2
  • Female volunteers admitted to the study must be using a reliable means of contraception and must have a negative blood or urine pregnancy test at least 7days ago
  • Patients or their legal representatives who have signed the informed consent form.

Exclusion Criteria:

  • Known brain or spinal cord metastases
  • Patients who have received chemotherapy within the previous 4 weeks
  • Patients who have received radiotherapy related tp Gastric cancer within 4weeks
  • Patients who have participated in other clinical study within the previous 4weeks
  • Pregnancy (absence to be confirmed by ß-hCG test) or lactation period
  • Human immunodeficiency virus(HIV) antibody (+)
  • Have active infection or serious concomitant systemic disorder incompatible with the study
  • Clinically hypertension or diabete mellitus not well controlled with medication
  • Clinically significant cardiac disease(e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction
  • Presence or history of malignancy other than Gastirc cancer within 5years
  • Have severe Neurologic or psychological disorder
  • Patients who have history of allery with this investigational drug(SB injection)
  • Obvious cognitive or physical impairment that would prevent participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01305993

Contact: Yong-oon Shin, Prof. 032-890-2548
Contact: Ji-yeon Lee, RN/BSc 032-890-1133

Korea, Republic of
Inha University Hospital Not yet recruiting
Incheon, Jung-gu, Korea, Republic of, 400-711
Contact: Yong-oon Shin, Prof.    032-890-2548   
Contact: Ji-yeon Lee, RN/BSc    032-890-1133   
Sponsors and Collaborators
SBPharmaceutical IND, Co., LTD
Principal Investigator: Yong-oon Shin, Prof Inha University Hospital

Additional Information:
SBP  This link exits the site

Responsible Party: Lee Dong-heum / executive director, SBPharmaceutical IND, Co., LTD Identifier: NCT01305993     History of Changes
Other Study ID Numbers: SB injection-G002
First Posted: March 1, 2011    Key Record Dates
Last Update Posted: March 1, 2011
Last Verified: February 2011

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases